CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
2025年1月23日 - 2:17PM
ビジネスワイヤ(英語)
Please replace the release dated January 22, 2025 with the
following corrected version due to multiple revisions.
The updated release reads:
EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT
WITH GPCR THERAPEUTICS INC.
Exicure, Inc. (Nasdaq: XCUR, “the Company”, “Exicure”), today
announced that on January 19, 2025, Exicure Inc. (“the Company”)
entered into a Share Purchase Agreement with GPCR Therapeutics
Inc., a Korean corporation (“GPCR”), pursuant to which the Company
acquired from GPCR all of the issued and outstanding equity
securities of GPCR Therapeutics USA Inc., a California corporation
(“GPCR USA”). The transactions completed under the Share Purchase
Agreement closed concurrently with execution. GPCR USA was, until
immediately prior to closing under the Share Purchase Agreement, a
wholly owned subsidiary of GPCR.
In connection with the closing of the Share Purchase Agreement,
the Company and GPCR entered into a License and Collaboration
Agreement (“L&C Agreement”) to further develop and
commercialize GPCR’s technologies related to certain intellectual
properties and patents. The L&C Agreement requires the Company
to make milestone payments to GPCR upon the achievement of specific
milestone events relating to clinical trials, marketing
authorizations, and net sales, as well as for the Company to pay a
recurring royalty payment based on at least 10% of net sales, as
set forth in the L&C Agreement.
About GPCR USA, Inc.
GPCR USA is a biotech company that is currently led by Dr. Pina
Cardarelli, the CSO and president of GPCR USA. The company has an
ongoing Phase 2 clinical trial focused on blood cancer patients,
particularly those eligible for hematopoietic stem cell
transplantation (HSCT). The trial involves the combined
administration of G-CSF, GPC-100 (Burixafor) and propranolol. Per
Dr. Cardarelli, "Two additional patients will receive treatment in
January 2025. GPCR USA plans to complete the administration of
GPC-100 to 20 patients by the end of April and aim to announce the
clinical trial results by September."
In December of last year, GPCR USA presented results at the
American Society of Hematology conference evaluating the impact of
inhibiting CXCR4 and ADRB2 (beta-2 adrenergic receptor) on stem
cell mobilization. Interim data from 10 patients for burixafor in
combination with propranolol and G-CSF is promising. Results
suggest that the treatment regimen can mobilize CD34+ stem cells
sufficiently for autologous stem cell transplant. Notably,
burixafor allowed for same day administration of both mobilizing
agent and leukapheresis. This fast kinetics of mobilization is
differentiated from the FDA approved plerixafor or motixafortide,
which require overnight pre-treatment prior to leukapheresis. The
median times to neutrophil and platelet engraftment, 11 and 14 days
respectively, are slightly less than what has been observed for
standard of care. Importantly, 100% of the patients met the primary
objective and the combination regimen exhibited excellent safety
profiles in patients receiving the new front line blood cancer
drug, Daratumumab. Dr. Cardarelli stated, "After completing patient
treatment, we will conduct follow-up observations until July and
then start data analysis," adding that positive results from the
GPC-100 trial could have a beneficial impact on attracting
additional investment and enhancing corporate value.
Currently, the ongoing clinical trials have met all primary end
points and are at the stage of deciding whether to proceed to Phase
3. A proposed double-blind clinical trial comparing the
mobilization agent Plerixafor with GPC-100 is under discussion.
Additionally, research has shown that the combination of GPC-100
and propranolol increases the number of specific T cells, which are
favorable for enhancing CAR-T (Chimeric Antigen Receptor T-cell)
response rates, and relevant papers are being published. Thus, this
could assist Exicure in expanding its additional pipeline for cell
and gene therapies.
Dr. Cardarelli suggested that in the future, it will be
essential to prioritize discussions with various partners based on
the likelihood of success and high return on investment. She
concluded, "If the hypotheses presented to GPCR USA are validated,
there may be potential G-Protein Coupled Receptor targets that
could be applicable to various diseases. We are considering steps
such as establishing collaborations with companies possessing
antibody manufacturing technologies, testing those technologies,
and conducting joint research on multiple G-Protein Coupled
Receptors.”
Dr. Cardarelli was an inventor of the CXCR4 antibody,
Ulocuplumab developed by BMS, and in 2019 she joined GPCR
Therapeutics evaluating the combination of CXCR4 and ADRB2. She
later served as the Chief Scientific Officer (CSO) of GPCR USA,
contributing to the establishment of GPCR USA, talent acquisition,
formation of a scientific advisory board, and the introduction of
cell analysis and high-throughput screening technologies. She also
successfully designed clinical trials for GPC-100 and secured FDA
orphan drug designation.
About Exicure, Inc.
Exicure, Inc. is an early-stage biotechnology company focused on
developing nucleic acid therapies targeting ribonucleic acid
against validated targets. Following its recent restructuring and
suspension of clinical and development activities, the Company is
exploring strategic alternatives to maximize stockholder value,
both with respect to its historical biotechnology assets and more
broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward looking
statements are those which are not historical in nature. They are
often identified by their inclusion of words such as “will,”
“anticipate,” “estimate,” “plan,” “should,” “expect,” “believe,”
“intend” and similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual outcomes to
differ materially from the outcomes expressed or implied by this
report. Such risks include, among others, the accuracy of
projections, targets, or plans, the possibility of listing
deficiencies, and the risk that Nasdaq will ultimately delist the
Company’s common stock. All such factors are difficult to predict
and may be beyond the Company’s control. The Company undertakes no
obligation and does not intend to update or revise any
forward-looking statements contained herein, except as required by
law or regulation. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this report.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250122516457/en/
Media Contact: Josh Miller 847-673-1700
media@exicuretx.com
Exicure (NASDAQ:XCUR)
過去 株価チャート
から 1 2025 まで 2 2025
Exicure (NASDAQ:XCUR)
過去 株価チャート
から 2 2024 まで 2 2025